Literature DB >> 10174325

Quality-of-life outcomes and the use of antihistamines in a French national population-based sample of patients with perennial rhinitis.

P D Pariente1, C LePen, F Los, J Bousquet.   

Abstract

Our primary objective in designing the first large-scale nationwide population-based survey in France was to assess the impact of perennial rhinitis on quality of life. Our secondary objective was to describe the use of drug treatment, including histamine H1 antagonists, in that population. A pollbase of 20,000 households was screened for symptoms of rhinitis. 16,786 households responded, including 35,615 patients aged over 15 years, giving an overall response rate of 84%. Using an algorithm, 1367 patients with probable perennial rhinitis were selected for a cross-sectional collection of data about the history of their condition, comorbidity, use of medical resources, sick leave and nasal symptom-related quality of life [according to the Medical Outcomes Study 36-Item Short-Form Questionnaire (SF-36)]. Finally, multivariate regression techniques were used to describe the relationship between quality-of-life scores and treatment subgroups, controlling for some other confounding factors. The point prevalence of perennial rhinitis was estimated to be 4.1% [95% confidence interval (CI): 3.9 to 4.3%]. Association of perennial rhinitis with a history of asthma was highly significant (13.4% in those with perennial rhinitis vs 3.8% in those without; odds ratio 3.26; p < 0.001). 38% of the patients with perennial rhinitis reported having taken regular medication during the last 3 months. Antihistamine use was associated with use of decongestant or topical nasal products in about one-third of patients. Four SF-36 dimensions (physical functioning, role physical, bodily pain, social functioning) showed significantly higher mean scores (indicating better quality of life) in patients receiving non-anticholinergic histamine H1 antagonist therapy, relative to those receiving other treatments, a difference that was maintained after controlling for gender, age, level of nasal symptoms, medical history of asthma and number of general practitioner visits. These results established the long term impact of perennial rhinitis on quality of life (generic and specific), and raised questions about appropriate therapy, since a positive association between current use of non-anticholinergic antihistamines with improvements on some SF-36 dimensional scores in patients with perennial rhinitis was observed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10174325     DOI: 10.2165/00019053-199712050-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  11 in total

Review 1.  Economic appraisal of asthma and COPD care: a literature review 1980-1991.

Authors:  M P Mölken; E K Van Doorslaer; F F Rutten
Journal:  Soc Sci Med       Date:  1992-07       Impact factor: 4.634

Review 2.  The economic costs of asthma: a review and conceptual model.

Authors:  K B Weiss; S D Sullivan
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

5.  Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire.

Authors:  E F Juniper; G H Guyatt; B Andersson; P J Ferrie
Journal:  Ann Allergy       Date:  1993-03

6.  Costs of hay fever in the United States in 1990.

Authors:  P McMenamin
Journal:  Ann Allergy       Date:  1994-07

Review 7.  International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group.

Authors: 
Journal:  Allergy       Date:  1994       Impact factor: 13.146

8.  Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history.

Authors:  B Sibbald; E Rink
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

9.  The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976-80 (NHANES II).

Authors:  P J Gergen; P C Turkeltaub
Journal:  J Allergy Clin Immunol       Date:  1992-10       Impact factor: 10.793

10.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

View more
  6 in total

Review 1.  [Allergic rhinitis. Immunological and neurogenic mechanisms].

Authors:  L Klimek; O Pfaar
Journal:  HNO       Date:  2011-12       Impact factor: 1.284

2.  The study of co-morbid conditions in adults with allergic rhinitis, from Mumbai, Maharashtra, India and their comparison with children.

Authors:  Asha Pherwani; Gauri Mankekar; Kashmira Chavan; Charissa Periera; Gaurav Bansode
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2009-03-31

3.  Early detection of allergic diseases in otorhinolaryngology.

Authors:  Ludger Klimek; Philip Schendzielorz
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2010-10-07

4.  Actual therapeutic management of allergic and hyperreactive nasal disorders.

Authors:  Claudia Rudack
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

5.  A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases.

Authors:  Zhaozhong Zhu; Phil H Lee; Mark D Chaffin; Wonil Chung; Po-Ru Loh; Quan Lu; David C Christiani; Liming Liang
Journal:  Nat Genet       Date:  2018-05-21       Impact factor: 38.330

6.  Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis.

Authors:  S Zielen; P Devillier; J Heinrich; H Richter; U Wahn
Journal:  Allergy       Date:  2017-08-10       Impact factor: 13.146

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.